News

INmune Bio: What's Left For Investors
INmune Bio's ATM offering raises $19M ahead of Phase II results, but disappointing data and dilution signal risks. Read here ...
NADPH Oxidase (NOX)-Replacement Therapies Market To Observe Stunning Growth During The Forecast Period (2025-2034) Across 7MM Delveinsight
The NOX-targeted therapy market is expected to expand significantly over the upcoming years as more therapies move into late-stage developmen ...